ascopubs.org23 天
Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
In May 2024, the US Food and Drug Administration (FDA) approved tarlatamab for treatment of patients with relapsed SCLC on the basis of the results of the phase II DeLLphi-301 trial. 3 Tarlatamab is a ...
UVA Today1 个月
Q&A: What’s Going on With Lung Cancer Research?
In August, UVA Cancer Center became the first in Virginia to offer lung cancer patients the new drug tarlatamab, approved in May as immunotherapy to supercharge the body’s immune system to fight small ...
来自MSN1 年
Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC
Tarlatamab is an investigational delta-like ligand 3 targeting Bispecific T-cell Engager ... The above BLA was based on data from the phase II DeLLphi-301 study, which evaluated tarlatamab ...
pharmaphorum3 天
FDA starts speedy review of Amgen’s lung cancer BiTE therapy
tarlatamab could reignite interest in DLL3, a target that suffered a major setback in 2019 when AbbVie abandoned the development of Rova-T, an anti-DLL3 antibody-drug conjugate, after a phase 3 ...
pharmaphorum7 个月
Amgen adds BiTE to its cancer range as FDA clears Imdelltra
Tarlatamab has been approved under the Imdelltra ... an anti-DLL3 antibody-drug conjugate, after a phase 3 failure in SCLC, and Imdelltra’s approval will embolden other companies working in ...